美股市场个股详情
MOR MorphoSys
- 17.915
- +0.025+0.14%
交易中 05/06 12:50 (美东)
27.03亿总市值-5455市盈率TTM
17.980最高价17.880最低价24.42万股成交量17.890今开17.890昨收438.16万成交额0.21%换手率亏损市盈率(静)1.51亿总股本18.30552周最高51.19市净率20.71亿流通值4.18552周最低--股息TTM1.16亿流通股37.961历史最高--股息率TTM0.56%振幅3.170历史最低17.940平均价1股每手
MorphoSys股票讨论区
登录发表评论
$MorphoSys(MOR.US$ MorphoSys Spokesperson Says "This Story Is Factually Wrong" In An Emailed Statement To Bloomberg News, In Response To STAT News' Adam Feuerstein Article Entitled, "Why Novartis Is Going To Walk Away From Its Acquisition"
Benzinga· 5 mins ago
Why Novartis is going to walk from its acquisition of MorphoSys (statnews.com)
Novartis said Monday that it intends to buy MorphoSys for just under $3 billion. The deal will not c...
Benzinga· 5 mins ago
Why Novartis is going to walk from its acquisition of MorphoSys (statnews.com)
Novartis said Monday that it intends to buy MorphoSys for just under $3 billion. The deal will not c...
1
3
Palantir's Q4 commercial business performance was 'bombastic, baller, incomprehensibly good', according to CEO Alex Karp. Coherent sees 'improving demand trends', expecting 'ongoing sequential improvement in revenue growth'. Chegg's Q1 guidance disappointed investors. NXP Semiconductors' Q4 results surpassed expectations. Novartis' acquisition of MorphoSys is viewed positively.
3
4
$MorphoSys(MOR.US$ MorphoSys' Pelabresib Improves All Four Hallmarks of Myelofibrosis in Phase 3 MANIFEST-2 Study
Pelabresib and ruxolitinib combination significantly reduced spleen size, with an SVR35 response rate nearly double that of placebo plus ruxolitinib Showed a strong positive trend in reducing symptom burden and a twofold increase in patients achieving both SVR35 and TSS50 versus placebo plus ruxolitinib Improved measures of anemia, including higher hemoglobin response rates, ...
Pelabresib and ruxolitinib combination significantly reduced spleen size, with an SVR35 response rate nearly double that of placebo plus ruxolitinib Showed a strong positive trend in reducing symptom burden and a twofold increase in patients achieving both SVR35 and TSS50 versus placebo plus ruxolitinib Improved measures of anemia, including higher hemoglobin response rates, ...
3
$MorphoSys(MOR.US$ stock is falling hard on Tuesday after the company released data from a Phase 3 clinical trial of pelabresib.
The study evaluated pelabresib as a treatment for myelofibrosis in combination with ruxolitinib. It included patients treated with these two drugs as well as a placebo arm just treated with ruxolitinib.
The results from the clinical trial saw pelabresib meet its primary endpoint. There was also statistical significance observed ...
The study evaluated pelabresib as a treatment for myelofibrosis in combination with ruxolitinib. It included patients treated with these two drugs as well as a placebo arm just treated with ruxolitinib.
The results from the clinical trial saw pelabresib meet its primary endpoint. There was also statistical significance observed ...
2
1
$MorphoSys(MOR.US$ The German pharmaceutical company said Monday its Phase 3 trial of pelabresib in combination with ruxolitinib in myelofibrosis patients found a statistically significant and clinically meaningful improvement in the portion of patients with a 35% or greater reduction in spleen volume after 24 weeks.![]()
$MorphoSys(MOR.US$ MorphoSys' Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction![]()
Implied volatility is a measure of the market's expectation of the potential price movements of the stock in the future. Here are the stocks with the most notable implied volatility today.
$MorphoSys(MOR.US$'s stock remained unchanged during the previous trading session. However, options volume was notable at 3.93K and the implied volatility percentile stood at an impressive 96.0%. This means that option traders are anticipating a signif...
$MorphoSys(MOR.US$'s stock remained unchanged during the previous trading session. However, options volume was notable at 3.93K and the implied volatility percentile stood at an impressive 96.0%. This means that option traders are anticipating a signif...
20
1
暂无评论
分析
目标价预测
暂无数据
热议
美股
综合热度
股票代码
最新价
涨跌幅
Jaguar8 : Grrrr
Jaguar8 : Even fake news abound in stock market
Trytosaveabit楼主 Jaguar8: Yup yup! It’s everywhere